Labcyte garners $21M in third venture round

Labcyte has wrapped its third round of venture capital with $21 million in new funding. The round was led by Cross Atlantic Partners and included Hambrecht & Quist Capital Management and the Bay Area Equity Fund, a fund managed by JPMorgan, as new investors. Their money will be employed to expand Labcyte's fluid handling business, which is sold to researchers who work with assay plates.

- read this press release for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.